Iambic Recruits Tom Daniel, M.D., to its Scientific Advisory Board

LA JOLLA, CA – Entos, Inc announces the recruitment of leading biotechnology executive Tom Daniel, M.D. to its Scientific Advisory Board (“SAB”).

Tom Daniel has more than 20 years of experience leading and building research and development organizations and leading investments in new companies at the forefront of the innovative application of science to healthcare. Recently he served as a Venture Partner at ARCH Venture Partners for five years following a decade as President of Global Research and Early Development at Celgene Corporation. He previously served in senior leadership roles at AmbRx, Amgen and Immunex. Tom was formerly a director at Juno, Epizyme, Sana, Larimar and Vir.  He currently serves as board chair at LocanaBio, Gate Therapeutics and Trotana, and is director at Vividion, Gossamer Bio, Aspen and Mozart. He chairs the Board of Managers of Life Science Cares-San Diego, is a Trustee of Reed College, is a director at Scripps Research and Chair of the Board of Overseers.  He also serves as senior advisor to several private biotechnology companies. A nephrologist and former academic investigator, he was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. Dr. Daniel received his M.D. from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed his residency in Internal Medicine at Massachusetts General Hospital.

“Tom Daniel brings a singular track record of biotechnology experience to the stellar Entos Scientific and Clinical Advisory Boards. We couldn’t be more pleased to benefit from his leadership as Entos enters its new chapter as a clinical-stage therapeutics company.”
- Tom Miller, Entos co-founder and CEO

‍

About Entos

Entos is disrupting the therapeutics landscape with its cutting-edge generative AI drug discovery platform. Headquartered in La Jolla, CA, the Entos team unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated breakthrough treatments. Entos stands alone in providing concrete demonstration of a fully AI-enabled platform to deliver high quality, differentiated drugs to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Entos team is advancing an internal pipeline of clinical assets to address urgent unmet patient need in oncology. Learn more about Entos' team, platform, and pipeline at www.entos.ai.

‍